Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| Chronic Obstructive Pulmonary Disease (COPD) |
📓
Comprehensive profiling of the gut microbiota in patients with chronic obstructive pulmonary disease of varying severity. PloS one (PLoS One ) Vol: 16 Issue 4 Pages: e0249944 Pub: 2021 Epub: 2021 Apr 9 Authors Chiu YC , Lee SW , Liu CW , Lin RC , Huang YC , Lan TY , Wu LS , Publication |
| Chronic Obstructive Pulmonary Disease (COPD) |
📓
Seabuckthorn Wuwei Pulvis attenuates chronic obstructive pulmonary disease in rat through gut microbiota-short chain fatty acids axis. Journal of ethnopharmacology (J Ethnopharmacol ) Vol: Issue Pages: 116591 Pub: 2023 May 3 Epub: 2023 May 3 Authors Wang J , Ren C , Jin L , Batu W , Publication |
| Chronic Obstructive Pulmonary Disease (COPD) |
📓
The Bidirectional Gut-Lung Axis in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine (Am J Respir Crit Care Med ) Vol: 207 Issue 9 Pages: 1145-1160 Pub: 2023 May 1 Epub: Authors Wang L , Cai Y , Garssen J , Henricks PAJ , Folkerts G , Braber S , Publication |
| Chronic Obstructive Pulmonary Disease (COPD) |
📓
The gut microbiome is a significant risk factor for future chronic lung disease. The Journal of allergy and clinical immunology (J Allergy Clin Immunol ) Vol: 151 Issue 4 Pages: 943-952 Pub: 2023 Apr Epub: 2022 Dec 29 Authors Liu Y , Teo SM , Méric G , Tang HHF , Zhu Q , Sanders JG , Vázquez-Baeza Y , Verspoor K , Vartiainen VA , Jousilahti P , Lahti L , Niiranen T , Havulinna AS , Knight R , Salomaa V , Inouye M , Publication |
| Chronic Obstructive Pulmonary Disease (COPD) |
📓
The Role of Gut Bacteriome in Asthma, Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnoea. Microorganisms (Microorganisms ) Vol: 10 Issue 12 Pages: Pub: 2022 Dec 13 Epub: 2022 Dec 13 Authors Bikov A , Dragonieri S , Csoma B , Mazzuca C , Finamore P , Rocchi G , Putignani L , Guarino M , Scarlata S , Publication |
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
